Randomised, placebo-controlled, double-blind clinical trial of β-sitosterol in patients with benign prostatic hyperplasia

The Lancet

Volumn 345, Issue 8964, 1995, Pages 1529-1532

  Berges, R R ^a   Windeler, J ^a   Trampisch, H J ^a   Senge, Th ^a   ss sitosterol study group ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PHYTOSTEROL; SITOSTEROL;

AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EPIGASTRIC PAIN; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; MICTURITION; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINE VOLUME; VERTIGO;

EID: 0029078027     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(95)91085-9     Document Type: Article

References (17)

1. The development of human benign prostatic hyperplasia with age
2. The incidence of benign prostatic hypertrophy
3. Symptom status and quality of life following prostatectomy
4. Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia
5. An inhibitor of 5-alpha-reductase, MK-906, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia
6. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia
7. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction
8. Alfuzosin for treatment of benign prostatic hypertrophy
9. Konservative, nicht-hormonelle Behandlung der benignen Prostata-hyperplasie
10. Clinical research criteria
11. Guide lines for investigation of benign prostatic hypertrophy
12. The international prostate symptom score (I-PSS) and quality of life assessment
13. Neue Therapieansätze bei der benignen Prostatahyperplasie
14. Alfuzosin for treatment of benign prostatic hypertrophy
15. Doxazosin treatment in patients with obstruction. A double blind placebo-controlled study
16. A three month double-blind study of Doxazosin as treatment of benign prostatic bladder outlet obstruction
17. The effect of prazosin in benign prostatic hypertrophy: a placebo-controlled double-blind study